AnnMohrbacherMD

Hematology • Los Angeles, CA

Associate Professor, Medicine, USC School of Medicine

Join to view full profile

Dr. Mohrbacher is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mohrbacher's full profile

Already have an account?

Office
1441 Eastlake Ave
Ste 8302E
Los Angeles, CA 90089
Phone+1 323-442-5100

Fax+1 323-442-5641

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1990 - 1993
Brigham and Women's HospitalResidency, Internal Medicine, 1987 - 1990
Harvard Medical SchoolClass of 1987

Certifications & Licensure

CA State Medical License 1993 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors:LA Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012

Clinical Trials

Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients Start of enrollment: 2004 Mar 01
Unknown status
Phase 2
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer Start of enrollment: 2005 Feb 01
Completed
Phase 1
Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2004 May 01
Completed
Phase 2
Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma Start of enrollment: 2006 Dec 01
Completed
Phase 1
Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma Start of enrollment: 2012 Jan 09
Terminated
Phase 2
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma Start of enrollment: 2012 Nov 19
Completed
Phase 1
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia Start of enrollment: 2013 Mar 06
Terminated
Phase 1
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Start of enrollment: 2014 Jul 07
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

2 citations
Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial.
Steffan T Nawrocki, Julian Olea, Claudia Villa Celi, Homa Dadrastoussi, Kaijin Wu
Clinical Cancer Research. 2023-12-15
118 citations
TRALI due to granulocyte-agglutinating human neutrophil antigen-3a (5b) alloantibodies in donor plasma: a report of 2 fatalities
A. Davoren, Brian R. Curtis, I.A. Shulman, Ann Mohrbacher, Jürgen Bux
Transfusion. 2003-05-01
290 citations
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Jeffrey A. Zonder, Ann Mohrbacher, Seema Singhal, Frits van Rhee, William I. Bensinger
Blood. 2012-07-19

Abstracts/Posters

Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans
Ann Mohrbacher, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Hypercalcemia in Cancer: Causes, Symptoms, and ManagementNovember 1st, 2023